Cyclic nucleotide phosphodiesterases (PDE) 3 and 4 in normal, malignant, and HTLV-I transformed human lymphocytes

Biochemical Pharmacology

Volumn 58, Issue 6, 1999, Pages 935-950

  Ekholm, Dag ^a,c   Mulloy, James C ^b   Gao, Guang ^a   Degerman, Eva ^c   Franchini, Genoveffa ^b   Manganiello, Vincent C ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b Basic Research Laboratory   (United States)

^c LUND UNIVERSITY   (Sweden)

Author keywords

Cyclic nucleotide phosphodiesterases; HTLV I; Human lymphocytes; PDE3; PDE4

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 [1 (3 AMINOPROPYL) 3 INDOLYL] 4 (1 METHYL 3 INDOLYL) 1H PYRROLE 2,5 DIONE; ADENYLATE CYCLASE ACTIVATOR; CILOSTAMIDE; CYCLIC AMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 3; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 4; ERBSTATIN; FORSKOLIN; HERBIMYCIN A; ISOBUTYLMETHYLXANTHINE; ISOENZYME; MESSENGER RNA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PHYTOHEMAGGLUTININ; PROTEIN KINASE C INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; REGULATOR PROTEIN; ROLIPRAM; TAX PROTEIN; TYRPHOSTIN; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; IMMUNOPATHOLOGY; INFLAMMATORY DISEASE; LEUKEMIA CELL LINE; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; NATURAL KILLER CELL; NEOPLASM; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADULT; B-LYMPHOCYTES; BENZOQUINONES; CELL DIVISION; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; ENZYME INHIBITORS; FORSKOLIN; GENE PRODUCTS, TAX; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; INTERLEUKIN-2; JURKAT CELLS; KILLER CELLS, NATURAL; LACTAMS, MACROCYCLIC; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTES; PROTEIN KINASE INHIBITORS; QUINONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 0032772196     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00188-4     Document Type: Article

References (85)

1. Kammer G.M. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol Today. 9:1988;222-229.
2. Beavo J. Multiple phosphodiesterase isoenzymes. Background, nomenclature and implications. Beavo J., Houslay M.D. Cyclic Nucleotide Phosphodiesterases Structure, Regulation and Drug Action . 1990;3-15 John Wiley, Chichester.
3. Conti M., Nemoz G., Sette C., Vicini E. Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocr Rev. 16:1995;370-389.
4. Manganiello V.C., Murata T., Taira M., Belfrage P., Degerman E. Diversity in cyclic nucleotide phosphodiesterase isoenzyme families. Arch Biochem Biophys. 322:1995;1-13.
5. Soderling S.H., Bayuga S.J., Beavo J.A. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem. 273:1998;15553-15558.
6. Fisher D., Smith J., Pillar J., St. Dennis S., Chang J. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem Biophys Res Commun. 246:1998;570-576.
7. Tenor H., Schudt C. Analysis of PDE isoenzyme profiles in cells and tissues by pharmacological methods. Schudt C., Dent G., Rabe K.F. Phosphodiesterase Inhibitors. 1996;21-40 Academic Press, London.
8. + T-lymphocytes Role in regulating proliferation and the biosynthesis of interleukin-2 . Br J Pharmacol. 118:1996;1945-1958.
9. + T lymphocytes. Clin Exp Allergy. 25:1995;616-624.
10. Epstein P.M., Mills J.S., Hersh E.M., Strada S.J., Thompson W.J. Activation of cyclic nucleotide phosphodiesterase from isolated human peripheral blood lymphocytes by mitogenic agents. Cancer Res. 40:1980;379-386.
11. Epstein P.M., Hachisu R. Cyclic nucleotide phosphodiesterase in normal and leukemic human lymphocytes and lymphoblasts. Adv Cyclic Nucleotide Protein Phosphorylation Res. 16:1984;303-324.
12. Ekholm D., Hemmer B., Gao G., Vergelli M., Martin R., Manganiello V. Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein. J Immunol. 159:1997;1520-1529.
13. Robicsek S.A., Blanchard D.K., Djeu J.Y., Krzanowski J.J., Szentivanyi A., Polson J.B. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem Pharmacol. 42:1991;869-877.
14. Hurwitz R.L., Hirsch K.M., Clark D.J., Holcombe V.N., Hurwitz M.Y. Induction of a calcium/calmodulin-dependent phosphodiesterase during phytohemagglutinin-stimulated lymphocyte mitogenesis. J Biol Chem. 265:1990;8901-8907.
15. Averill L.E., Stein R.L., Kammer G.M. Control of human T-lymphocyte interleukin-2 production by a cAMP-dependent pathway. Cell Immunol. 115:1988;88-99.
16. Mary D., Aussel C., Ferrua B., Fehlmann M. Regulation of interleukin 2 synthesis by cAMP in human T cells. J Immunol. 139:1987;1179-1184.
17. Skålhegg B.S., Tasken K., Hansson V., Huitfeldt H.S., Jahnsen T., Lea T. Location of cAMP-dependent protein kinase type I with the TCR-CD3 complex. Science. 263:1994;84-87.
18. Cook S.J., McCormick F. Inhibition by cAMP of Ras-dependent activation of Raf. Science. 262:1993;1069-1072.
19. Wu J., Dent P., Jelinek T., Wolfman A., Weber M.J., Sturgill T.W. Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3′,5′-monophosphate. Science. 262:1993;1065-1069.
20. Hsueh Y.P., Lai M.Z. c-Jun N-terminal kinase but not mitogen-activated protein kinase is sensitive to cAMP inhibition in T lymphocytes. J Biol Chem. 270:1995;18094-18098.
21. Tamir A., Granot Y., Isakov N. Inhibition of T lymphocyte activation by cAMP is associated with down-regulation of two parallel mitogen-activated protein kinase pathways, the extracellular signal-related kinase and c-Jun N-terminal kinase. J Immunol. 157:1996;1514-1522.
22. Alava M.A., DeBell K.E., Conti A., Hoffman T., Bonvini E. Increased intracellular cyclic AMP inhibits inositol phospholipid hydrolysis induced by perturbation of the T cell receptor/CD3 complex but not by G-protein stimulation. Association with protein kinase A-mediated phosphorylation of phospholipase C-γ1. Biochem J. 284:1992;189-199.
23. Park D.J., Min H.K., Rhee S.G. Inhibition of CD3-linked phospholipase C by phorbol ester and by cAMP is associated with decreased phosphotyrosine and increased phosphoserine contents of PLC-γ1. J Biol Chem. 267:1992;1496-1501.
24. Franchini G. Molecular mechanisms of human T-cell leukemia/lymphotropic virus type I infection. Blood. 86:1995;3619-3639.
25. Jacobson S., Raine C.S., Mingioli E.S., McFarlin D.E. Isolation of an HTLV-1-like retrovirus from patients with tropical spastic paraparesis. Nature. 331:1988;540-543.
26. Hollsberg P. Pathogenesis of chronic progressive myelopathy associated with human T-cell lymphotropic virus type I. Acta Neurol Scand Suppl. 169:1997;86-93.
27. Rosenblatt J.D., Giorgi J.V., Golde D.W., Ezra J.B., Wu A., Winberg C.D., Glaspy J., Wachsman W., Chen I.S. Integrated human T-cell leukemia virus II genome in CD8+ T cells from a patient with "atypical" hairy cell leukemia Evidence for distinct T and B cell lymphoproliferative disorders . Blood. 71:1988;363-369.
28. Migone T.S., Lin J.X., Cereseto A., Mulloy J.C., O'Shea J.J., Franchini G., Leonard W.J. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science. 269:1995;79-81.
29. Xu X., Kang S.H., Heidenreich O., Okerholm M., O'Shea J.J., Nerenberg M.I. Constitutive activation of different Jak tyrosine kinases in human T cell leukemia virus type 1 (HTLV-1) tax protein or virus-transformed cells. J Clin Invest. 96:1995;1548-1555.
30. Weber-Nordt R.M., Egen C., Wehinger J., Ludwig W., Gouilleux-Gruart V., Mertelsmann R., Finke J. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood. 88:1996;809-816.
31. Ahmad F, Gao G, Wang L-M, Rahn-Landstrom T, Degerman E, Pierce JH and Manganiello VC, Interleukin-3 and interleukin-4 activate cyclic nucleotide phosphodiesterases 3 (PDE3) and 4 (PDE4) by different mechanisms in FDCP2 myeloid cells. J Immunol 162: 4864-4875.
32. Smith C.J., Vasta V., Degerman E., Belfrage P., Manganiello V.C. Hormone-sensitive cyclic GMP-inhibited cyclic AMP phosphodiesterase in rat adipocytes. Regulation of insulin- and cAMP-dependent activation by phosphorylation. J Biol Chem. 266:1991;13385-13390.
33. Rahn T., Ridderstrale M., Tornqvist H., Manganiello V., Fredrikson G., Belfrage P., Degerman E. Essential role of phosphatidylinositol 3-kinase in insulin-induced activation and phosphorylation of the cGMP-inhibited cAMP phosphodiesterase in rat adipocytes. Studies using the selective inhibitor wortmannin. FEBS Lett. 350:1994;314-318.
34. Wijkander J., Rahn-Landström T., Manganiello V., Belfrage P., Degerman E. Insulin-induced phosphorylation and activation of phosphodiesterase 3B in rat adipocytes Possible role for protein kinase B but not mitogen-activated protein kinase or p70 S6 kinase . Endocrinology. 139:1998;219-227.
35. Zhao A.Z., Zhao H., Teague J., Fujimoto W., Beavo J.A. Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. Proc Natl Acad Sci USA. 94:1997;3223-3228.
36. Taylor C.C., Limback D., Terranova P.F. Src tyrosine kinase activity in rat thecal-interstitial cells and mouse TM3 Leydig cells is positively associated with cAMP-specific phosphodiesterase activity. Mol Cell Endocrinol. 126:1997;91-100.
37. Salahuddin S.Z., Markham P.D., Wong-Staal F., Franchini G., Kalyanaraman V.S., Gallo R.C. Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. Virology. 129:1983;51-64.
38. Watanabe T., Seiki M., Hirayama Y., Yoshida M. Human T-cell leukemia virus type I is a member of the African subtype of simian viruses (STLV). Virology. 148:1986;385-388.
39. Popovic M., Sarin P.S., Robert-Gurroff M., Kalyanaraman V.S., Mann D., Minowada J., Gallo R.C. Isolation and transmission of human retrovirus (human T-cell leukemia virus). Science. 219:1983;856-859.
40. Aldovini A., De Rossi A., Feinberg M.B., Wong-Staal F., Franchini G. Molecular analysis of a deletion mutant provirus of type I human T-cell lymphotropic virus Evidence for a doubly spliced x-lor mRNA . Proc Natl Acad Sci USA. 83:1986;38-42.
41. Poiesz B.J., Ruscetti F.W., Gazdar A.F., Bunn P.A., Minna J.D., Gallo R.C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 77:1980;7415-7419.
42. Mulloy J.C., Migone T.S., Ross T.M., Ton N., Green P.L., Leonard W.J., Franchini G. Human and simian T-cell leukemia viruses type 2 (HTLV-2 and STLV-2(pan-p)) transform T cells independently of Jak/STAT activation. J Virol. 72:1998;4408-4412.
43. Kalyanaraman V.S., Sarngadharan M.G., Robert-Guroff M., Miyoshi I., Golde D., Gallo R.C. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science. 218:1982;571-573.
44. + cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J Immunol. 148:1992;1359-1366.
45. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248-254.
46. Beavo J.A., Reifsnyder D.H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci. 11:1990;150-155.
47. Meacci E., Taira M., Moos M. Jr, Smith C.J., Movsesian M.A., Degerman E., Belfrage P., Manganiello V. Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. Proc Natl Acad Sci USA. 89:1992;3721-3725.
48. Miki T., Taira M., Hockman S., Shimada F., Lieman J., Napolitano M., Ward D., Makino H., Manganiello V.C. Characterization of the cDNA and gene encoding human PDE3B, the cGIP1 isoform of the human cyclic GMP-inhibited cyclic nucleotide phosphodiesterase family. Genomics. 36:1996;476-485.
49. Bolger G., Michaeli T., Martins T., St. John T., Steiner B., Rodgers L., Riggs M., Wigler M., Ferguson K. A family of human phosphodiesterases homologous to the dunce learning and memory gene product of Drosophila melanogaster are potential targets for antidepressant drugs. Mol Cell Biol. 13:1993;6558-6571.
50. m, rolipram-sensitive, cAMP-specific phosphodiesterase from human brain. Cloning and expression of cDNA, biochemical characterization of recombinant protein, and tissue distribution of mRNA. J Biol Chem. 268:1993;6470-6476.
51. Engels P., Sullivan M., Müller T., Löbbert H. Molecular cloning and functional expression in yeast of a human cAMP-specific phosphodiesterase subtype (PDE IV-C). FEBS Lett. 358:1995;305-310.
52. Michaeli T., Bloom T.J., Martins T., Loughney K., Ferguson K., Riggs M., Rodgers L., Beavo J.A., Wigler M. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J Biol Chem. 268:1993;12925-12932.
53. Jiang X., Li J., Paskind M., Epstein P.M. Inhibition of calmodulin-dependent phosphodiesterase induces apoptosis in human leukemic cells. Proc Natl Acad Sci USA. 93:1996;11236-11241.
54. Torphy T.J. Phosphodiesterase isozymes Molecular targets for novel antiasthma agents . Am J Respir Crit Care Med. 157:1998;351-370.
55. Dent G., Giembycz M.A. Interaction of PDE4 inhibitors with enzymes and cell functions. Schudt C., Dent G., Rabe K.F. Phosphodiesterase Inhibitors. 1996;111-126 Academic Press, London.
56. Good L., Maggirwar S.B., Sun S.C. Activation of the IL-2 gene promoter by HTLV-I Tax involves induction of NF-AT complexes bound to the CD28-responsive element. EMBO J. 15:1996;3744-3750.
57. tax protein in the human T-cell line, Jurkat. J Virol. 63:1989;3220-3226.
58. Grassmann R., Dengler C., Muller-Fleckenstein I., Fleckenstein B., McGuire K., Dokhelar M.C., Sodroski J.G., Haseltine W.A. Transformation to continuous growth of primary human T lymphocytes by human T-cell leukemia virus type I X-region genes transduced by a Herpesvirus saimiri vector. Proc Natl Acad Sci USA. 86:1989;3351-3355.
59. Ohno T., Kato N., Ishii C., Shimizu M., Ito Y., Tomono S., Kawazu S. Genistein augments cyclic adenosine 3′5′-monophosphate(cAMP) accumulation and insulin release in MIN6 cells. Endocr Res. 19:1993;273-285.
60. Ho A.K., Wiest R., Ogiwara T., Murdoch G., Chik C.L. Potentiation of agonist-stimulated cyclic AMP accumulation by tyrosine kinase inhibitors in rat pinealocytes. J Neurochem. 65:1995;1597-1603.
61. Keppens S. Effect of genistein on both basal and glucagon-induced levels of cAMP in rat hepatocytes. Biochem Pharmacol. 50:1995;1303-1304.
62. Kip1) of cyclin-dependent kinase 4 activation. Cell. 79:1994;487-496.
63. Engels P., Fichtel K., Löbbert H. Expression and regulation of human and rat phosphodiesterase type IV isogenes. FEBS Lett. 350:1994;291-295.
64. Essayan D.M., Kagey-Sobotka A., Lichtenstein L.M., Huang S.K. Differential regulation of human antigen-specific Th1 and Th2 lymphocyte responses by isozyme selective cyclic nucleotide phosphodiesterase inhibitors. J Pharmacol Exp Ther. 282:1997;505-512.
65. Santini F., Beaven M.A. Nonselective actions of herbimycin A. Immunol Today. 14:1993;369-370.
66. Pan X., Arauz E., Krzanowski J.J., Fitzpatrick D.F., Polson J.B. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem Pharmacol. 48:1994;827-835.
67. Souness J.E., Hassall G.A., Parrott D.P. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol. 44:1992;857-866.
68. Matousovic K., Grande J.P., Chini C.C., Chini E.N., Dousa T.P. Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-III and type-IV suppress mitogenesis of rat mesangial cells. J Clin Invest. 96:1995;401-410.
69. Drees M., Zimmermann R., Eisenbrand G. 3′,5′-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res. 53:1993;3058-3061.
70. Chen T.C., Hinton D.R., Zidovetzki R., Hofman F.M. Up-regulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab Invest. 78:1998;165-174.
71. Fujiwara H., Arima N., Otsubo H., Matsushita K., Hidaka S., Arimura K., Kukita T., Yamaguchi K., Tanaka H. Vesnarinone exhibits antitumor effect against myeloid leukemia cells via apoptosis. Exp Hematol. 25:1997;1180-1186.
72. Mentz F., Mossalayi M.D., Ouaaz F., Baudet S., Issaly F., Ktorza S., Semichon M., Binet J.L., Merle-Beral H. Theophylline synergizes with chlorambucil in inducing apoptosis of B-chronic lymphocytic leukemia cells. Blood. 88:1996;2172-2182.
73. Hatae T., Hara H., Kobayashi T., Watanabe T. The effect of rolipram on the production of cytokines in HTLV-I infected cell lines and peripheral blood mononuclear cells of patients with HTLV-I-associated myelopathy (HAM). J Neurol Sci. 148:1997;87-94.
74. Tsujino A., Nakamura T., Nishiura Y., Shirabe S., Furuya T., Goto H., Kawakami A., Eguchi K., Nagataki S. Pentoxifylline down-regulates adhesion molecule expression and inflammatory cytokine production in cultured peripheral blood mononuclear cells from patients with HTLV-I-associated myelopathy. J Neuroimmunol. 73:1997;191-196.
75. Moller D.R., Wysocka M., Greenlee B.M., Ma X., Wahl L., Trinchieri G., Karp C.L. Inhibition of human interleukin-12 production by pentoxifylline. Immunology. 91:1997;197-203.
76. Rieckmann P., Weber F., Gunther A., Martin S., Bitsch A., Broocks A., Kitze B., Weber T., Borner T., Poser S. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis. J Neuroimmunol. 64:1996;193-200.
77. Angel J.B., Saget B.M., Walsh S.P., Greten T.F., Dinarello C.A., Skolnik P.R., Endres S. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication. AIDS. 9:1995;1137-1144.
78. Ross S.E., Williams R.O., Mason L.J., Mauri C., Marinova-Mutafchieva L., Malfait A.M., Maini R.N., Feldmann M. Suppression of TNF-α expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol. 159:1997;6253-6259.
79. Sommer N., Loschmann P.A., Northoff G.H., Weller M., Steinbrecher A., Steinbach J.P., Lichtenfels R., Meyermann R., Riethmuller A., Fontana A., Dichgans J., Martin R. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med. 1:1995;244-248.
80. Genain C.P., Roberts T., Davis R.L., Nguyen M.H., Uccelli A., Faulds D., Li Y., Hedgpeth J., Hauser S.L. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc Natl Acad Sci USA. 92:1995;3601-3605.
81. Dinter H., Onuffer J., Faulds D., Perez H.D. Phosphodiesterase type IV inhibitors in the treatment of multiple sclerosis. J Mol Med. 75:1997;95-102.
82. Rott O., Cash E., Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol. 23:1993;1745-1751.
83. Liang L., Beshay E., Prud'homme G.J. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice. Diabetes. 47:1998;570-575.
84. Hatzelmann A., Engelstätter R., Morley J., Mazzoni L. Enzymatic and functional aspects of dual-selective PDE3/4 inhibitors. Schudt C., Dent G., Rabe K.F. Phosphodiesterase Inhibitors. 1996;147-160 Academic Press, London.
85. Nicholson CD and Shahid M, Inhibitors of cyclic nucleotide phosphodiesterase isoenzymes - Their potential utility in the therapy of asthma. Pulm Pharmacol 7: 1-17, 1994.